Yes, you can travel with Prograf. Carry the medication in its original prescription container, accompanied by a copy of the prescription or a doctor's letter. Airport security may inspect the medication, but it will not be restricted as a controlled substance in the UK.
Prograf tablets are typically round, white (0.5 mg and 1 mg) or pink (5 mg), and are imprinted with “A-10” or “A-15” depending on the strength. Checking the imprint against the pharmacy label helps verify authenticity.
Tacrolimus can be detected in blood or urine but is not commonly screened for in standard occupational or sports drug tests. However, if a specific test for immunosuppressants is ordered, the presence of tacrolimus will be reported.
Aviation medical authorities require that any medication potentially causing neuro-cognitive impairment be disclosed. Since tacrolimus can cause tremor or dizziness, pilots must be evaluated regularly and may need a medical exemption to continue flying.
Tacrolimus was discovered in 1984 from the soil bacterium Streptomyces tsukubaensis in Japan. It was first approved for organ transplantation in the early 1990s and marketed as Prograf by Astellas Pharma.
Both drugs inhibit calcineurin, but tacrolimus (Prograf) generally achieves similar immunosuppression at lower blood concentrations and may have a more favorable side-effect profile concerning gingival hyperplasia and hirsutism. Choice between them depends on individual response and tolerability.
Both contain the same active ingredient, but bioequivalence can vary. Switching should only occur under medical supervision, with close monitoring of trough levels to ensure consistent immunosuppression.
Tacrolimus is stable at room temperature. Prolonged exposure to temperatures below 15 °C or above 30 °C may affect tablet integrity. If stored in a cooler, keep it in a sealed container and avoid freezing.
Prograf is a high-cost, specialty medication used for transplant patients. UK NHS and private insurers often require clinical justification to ensure appropriate use before approving reimbursement.
Prograf is a prescription-only medication (POM) marketed in the United Kingdom by Astellas Pharma. Its sole active ingredient is tacrolimus, an immunosuppressant that belongs to the class of calcineurin inhibitors. Prograf is supplied as oral pills in strengths of 0.5 mg, 1 mg, and 5 mg. The drug is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is primarily used to prevent organ rejection after transplantation. Because tacrolimus modulates the immune system, it is occasionally considered for severe autoimmune conditions, but such uses are off-label in the UK.
Tacrolimus exerts its effect by binding to the intracellular protein FKBP-12 (FK506-binding protein). The tacrolimus-FKBP-12 complex then inhibits the enzyme calcineurin, a phosphatase essential for activating T-lymphocytes. By blocking calcineurin, tacrolimus reduces the production of interleukin-2 (IL-2) and other cytokines, thereby diminishing the proliferation and activation of T-cells that would otherwise attack a transplanted organ.
Approved (UK) indications
These indications are supported by the MHRA and based on robust clinical trial data demonstrating reduced graft rejection rates when tacrolimus is part of a multi-drug immunosuppressive regimen.
Tacrolimus has been investigated for several severe autoimmune diseases, including:
Disclaimer: These uses are not approved by the MHRA. Off-label prescribing must be supervised by a specialist, and the risk-benefit profile should be assessed individually.
Ideal candidates
Absolute contraindications
Relative contraindications & special considerations
These effects are usually dose-related and may improve with dose adjustment.
If any of these occur, seek immediate medical attention.
Patients should provide a full medication list-including over-the-counter products and herbal supplements-to their healthcare team.
Regular follow-up appointments with the transplant or immunology team are essential to maintain therapeutic efficacy while minimizing toxicity.
This article provides educational information about Prograf and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
